Search Medical Condition
Please enter condition
Please choose location from dropdown

Malaga, Antequera Clinical Trials

A listing of Malaga, Antequera clinical trials actively recruiting patients volunteers.

RESULTS

Found (123) clinical trials

A Study of MM-121 in Combination With Chemotherapy Versus Chemotherapy Alone in Heregulin Positive NSCLC

This study is a randomized, open-label, international, multi-center, phase 2 study in patients with Heregulin-positive NSCLC histologically classified as adenocarcinoma that have progressed following no more than two systemic therapies for locally advanced or metastatic disease, one of which must have been a platinum containing regimen. All patients will initially ...

Phase

ODM-201 vs Androgen Deprivation Therapy in Hormone na ve Prostate Cancer

ODM 201 will be administered as oral 300-mg tablets. The dose of study drug to be administered is 600 milligrams (mg) (2 x 300-mg tablets) twice daily (bid) for a daily dose of 1200 mg. It is recommended that ODM-201 be taken with food. Subjects who have clinical benefit at ...

Phase

This Clinical Study is to Test Efficacy and Safety of BT595 in Chronic Primary Immune Thrombocytopenia (ITP)

The main purpose of this study is to assess the efficacy and safety of BT595 in adult subjects with chronic ITP. The primary objective of this study is to determine the rate of subjects with a response. A response is defined as a platelet count of 3010^9/L and at least ...

Phase

Localized High-Risk Soft Tissue Sarcomas Of The Extremities And Trunk Wall In Adults: An Integrating Approach Comprising Standard Vs Histotype-Tailored Neoadjuvant Chemotherapy

This is a randomized Phase III clinical trial in the setting of localized high-risk soft tissue sarcomas (STS). This study will compare a standard neoadjuvant chemotherapy with epirubicin plus ifosfamide versus a histology-driven chemotherapy, i.e. a chemotherapy tailored to the specific histology within the family of adult STS. Chemotherapy will ...

Phase

Clinical and Device Functional Assessment of Real World ICD Patients

For these reasons, it is very important to observe the clinical practice on a large variety of centers and countries, with the objective to collect long term safety and performance data in patients undergoing ICD/CRT-D device implantation (first implant, replacement or upgrade). The safety and performance of the ICDs can ...

Phase N/A

Phase 3 Trial of Blinatumomab vs Standard Chemotherapy in Pediatric Subjects With HR First Relapse B-precursor ALL

Patients will be randomized in a 1:1 ratio to receive either one cycle of blinatumomab or one block of standard high-risk consolidation chemotherapy. Blinatumomab is administered as a continuous intravenous infusion (CIVI). One cycle of blinatumomab treatment includes 4 weeks of CIVI of blinatumomab. After completing consolidation therapy, the patients ...

Phase

PRORADIUM: Prospective Multi-centre Study of Prognostic Factors in CRPC Patients Treated With Radium-223.

This is a non-interventional prospective study in metastatic CRPC designed to explore biomarkers, composed by patients treated with Radium-223. Key inclusion criteria: a) histological confirmation of prostate cancer; b) documented criteria (PCWG2) for CRPC; c) availability of tumour tissue; d) candidate for standard treatment with Radium-223. Primary end point: to ...

Phase N/A

Panobinostat/Bortezomib/Dexamethasone in Relapsed or Relapsed-and-refractory Multiple Myeloma

The purpose of this study is to investigate the safety and efficacy of three different regimens of PAN (20 mg TIW, 20 mg BIW, and 10 mg TIW) in combination with s.c. BTZ and Dex and to provide exposure, safety and efficacy data to identify the optimal regimen of PAN ...

Phase

PROSENZA: Prospective Multi-Centre Study of Prognostic Factors in CRPC Patients Treated With Enzalutamide.

This is a non-interventional prospective study in metastatic CRPC designed to explore biomarkers, composed by patients treated with Enzalutamide. Key inclusion criteria: a) histological confirmation of prostate cancer; b) documented criteria (PCWG2) for CRPC; c) availability of tumour tissue; d) candidate for standard treatment with enzalutamide. Primary end point: to ...

Phase N/A

PROSTAC: Prospective Multi-centre Study of Prognostic Factors in CRPC Patients Treated With Docetaxel or Cabazitaxel.

This is a non-interventional prospective study in metastatic CRPC designed to explore biomarkers, composed by two cohorts of patients treated with docetaxel or cabazitaxel. Key inclusion criteria: a) histological confirmation of prostate cancer; b) documented criteria (PCWG2) for CRPC; c) availability of tumour tissue; d) candidate for standard treatment with ...

Phase N/A